CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 18 enrolled
Drug / intervention
Midomafetamine HCl +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02427568
NCT02427568Phase 2Completed

A Randomized, Double-Blind, Placebo-Controlled Phase 2 Pilot Study of MDMA-Assisted Psychotherapy for Anxiety Associated With a Life-Threatening Illness

Resilient Pharmaceuticals·interventional·Posted Apr 28, 2015·Updated Jun 5, 2025

In Brief

A Phase 2 clinical trial evaluating Midomafetamine HCl, Placebo, and 1 other intervention for Anxiety. Completed, enrolled 18 participants across 1 site.

Detailed Summary

The goal of this clinical trial is to learn if MDMA-assisted therapy is safe and effective in people with anxiety associated with a life-threatening illness. The main question it aims to answer is: Does anxiety decrease in people receiving two sessions of MDMA-assisted therapy? Researchers will compare people receiving placebo with therapy to people receiving MDMA-assisted therapy. * Participants will undergo three non-drug preparatory therapy sessions before their first blinded session of MDMA or placebo with therapy. * Each medication session will be followed by three non-drug integrative therapy sessions. * After the second blinded medication session, participants receiving MDMA will complete a third open-label medication session. * Participants who received placebo will be given the option to crossover and receive three sessions of assisted therapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAnxiety
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedApr 28, 2015
Enrollment StartMay 14, 2015
Primary CompletionApr 25, 2017
Study CompletionMay 17, 2018
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 11.2 years ago

Interventions

Midomafetamine HCldrug

Two sessions of MDMA-assisted therapy lasting six to eight hours, scheduled two to four weeks apart.

Placebodrug

Two sessions of placebo with therapy lasting six to eight hours, scheduled two to four weeks apart.

Therapybehavioral

Manualized therapy